JP7391367B2 - 前段階の精巣胚細胞腫瘍の早期発見 - Google Patents
前段階の精巣胚細胞腫瘍の早期発見 Download PDFInfo
- Publication number
- JP7391367B2 JP7391367B2 JP2019521755A JP2019521755A JP7391367B2 JP 7391367 B2 JP7391367 B2 JP 7391367B2 JP 2019521755 A JP2019521755 A JP 2019521755A JP 2019521755 A JP2019521755 A JP 2019521755A JP 7391367 B2 JP7391367 B2 JP 7391367B2
- Authority
- JP
- Japan
- Prior art keywords
- mir
- pcr
- tin
- cdna
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title description 29
- 208000032320 Germ cell tumor of testis Diseases 0.000 title description 8
- 208000002918 testicular germ cell tumor Diseases 0.000 title description 8
- 108091084261 miR-371a stem-loop Proteins 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 50
- 238000011529 RT qPCR Methods 0.000 claims description 48
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 43
- 230000014509 gene expression Effects 0.000 claims description 36
- 239000002299 complementary DNA Substances 0.000 claims description 31
- 210000002966 serum Anatomy 0.000 claims description 27
- 238000003752 polymerase chain reaction Methods 0.000 claims description 20
- 230000002381 testicular Effects 0.000 claims description 20
- 238000013459 approach Methods 0.000 claims description 11
- 238000007847 digital PCR Methods 0.000 claims description 10
- 208000020082 intraepithelial neoplasia Diseases 0.000 claims description 10
- 238000010804 cDNA synthesis Methods 0.000 description 43
- 239000002679 microRNA Substances 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 31
- 239000000523 sample Substances 0.000 description 30
- 108020004635 Complementary DNA Proteins 0.000 description 28
- 239000012472 biological sample Substances 0.000 description 25
- 108091070501 miRNA Proteins 0.000 description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 238000003199 nucleic acid amplification method Methods 0.000 description 17
- 108020004707 nucleic acids Proteins 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 17
- 150000007523 nucleic acids Chemical class 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 15
- 230000003321 amplification Effects 0.000 description 15
- 210000001124 body fluid Anatomy 0.000 description 12
- 239000010839 body fluid Substances 0.000 description 12
- 238000010839 reverse transcription Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 108700011259 MicroRNAs Proteins 0.000 description 11
- 210000004602 germ cell Anatomy 0.000 description 11
- 238000013500 data storage Methods 0.000 description 10
- 208000024313 Testicular Neoplasms Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 206010057644 Testis cancer Diseases 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 201000003120 testicular cancer Diseases 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- 238000002123 RNA extraction Methods 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 108091032902 miR-93 stem-loop Proteins 0.000 description 7
- 210000001550 testis Anatomy 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 208000021309 Germ cell tumor Diseases 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 206010011498 Cryptorchism Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 201000000160 cryptorchidism Diseases 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000011474 orchiectomy Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 208000009458 Carcinoma in Situ Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000011157 data evaluation Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 206010020488 hydrocele Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 201000004933 in situ carcinoma Diseases 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091067269 Homo sapiens miR-371a stem-loop Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 201000000331 Testicular germ cell cancer Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000117 blood based biomarker Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008960 regulation of mRNA stability Effects 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022055537A JP2022088555A (ja) | 2016-11-02 | 2022-03-30 | 前段階の精巣胚細胞腫瘍の早期発見 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196813.6 | 2016-11-02 | ||
| EP16196813 | 2016-11-02 | ||
| PCT/EP2017/078079 WO2018083186A1 (en) | 2016-11-02 | 2017-11-02 | Early detection of preliminary stages of testicular germ cell tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022055537A Division JP2022088555A (ja) | 2016-11-02 | 2022-03-30 | 前段階の精巣胚細胞腫瘍の早期発見 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532653A JP2019532653A (ja) | 2019-11-14 |
| JP2019532653A5 JP2019532653A5 (enExample) | 2020-12-03 |
| JP7391367B2 true JP7391367B2 (ja) | 2023-12-05 |
Family
ID=57223558
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521755A Active JP7391367B2 (ja) | 2016-11-02 | 2017-11-02 | 前段階の精巣胚細胞腫瘍の早期発見 |
| JP2022055537A Pending JP2022088555A (ja) | 2016-11-02 | 2022-03-30 | 前段階の精巣胚細胞腫瘍の早期発見 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022055537A Pending JP2022088555A (ja) | 2016-11-02 | 2022-03-30 | 前段階の精巣胚細胞腫瘍の早期発見 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11643690B2 (enExample) |
| EP (1) | EP3535417B9 (enExample) |
| JP (2) | JP7391367B2 (enExample) |
| CN (1) | CN109890979B (enExample) |
| AU (1) | AU2017353410B2 (enExample) |
| CA (1) | CA3038010A1 (enExample) |
| ES (1) | ES2952061T3 (enExample) |
| PL (1) | PL3535417T3 (enExample) |
| WO (1) | WO2018083186A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116121372B (zh) * | 2022-09-09 | 2025-09-19 | 清远市人民医院 | 一种鉴别中枢系统淋巴瘤和胶质母细胞瘤的miRNA标志物组合、试剂盒及应用 |
| CN120519585B (zh) * | 2025-07-23 | 2025-10-03 | 湖南工程学院 | 一种基于PER驱动Split G4/ThT级联检测睾丸生殖细胞瘤miRNA的探针体系及方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101363057B (zh) | 2008-09-09 | 2011-11-09 | 浙江理工大学 | 一种生物样本中miRNA绝对表达量的检测方法 |
| US20120107825A1 (en) * | 2010-11-01 | 2012-05-03 | Winger Edward E | Methods and compositions for assessing patients with reproductive failure using immune cell-derived microrna |
| CN104080911A (zh) * | 2011-11-30 | 2014-10-01 | 不来梅大学 | miRNA在胎盘组织中的表达 |
| CN104844566B (zh) * | 2014-12-12 | 2018-05-18 | 合肥中科普瑞昇生物医药科技有限公司 | 一种新型结构的激酶抑制剂 |
| DK3289095T5 (da) | 2015-04-29 | 2019-07-29 | Mirdetect Gmbh | Detektering af nukleinsyremolekyler |
| US10136952B2 (en) * | 2016-06-16 | 2018-11-27 | Zimmer, Inc. | Soft tissue balancing in articular surgery |
-
2017
- 2017-11-02 JP JP2019521755A patent/JP7391367B2/ja active Active
- 2017-11-02 US US16/341,383 patent/US11643690B2/en active Active
- 2017-11-02 CA CA3038010A patent/CA3038010A1/en active Pending
- 2017-11-02 CN CN201780067302.2A patent/CN109890979B/zh active Active
- 2017-11-02 PL PL17800438.8T patent/PL3535417T3/pl unknown
- 2017-11-02 EP EP17800438.8A patent/EP3535417B9/en active Active
- 2017-11-02 ES ES17800438T patent/ES2952061T3/es active Active
- 2017-11-02 WO PCT/EP2017/078079 patent/WO2018083186A1/en not_active Ceased
- 2017-11-02 AU AU2017353410A patent/AU2017353410B2/en active Active
-
2022
- 2022-03-30 JP JP2022055537A patent/JP2022088555A/ja active Pending
Non-Patent Citations (3)
| Title |
|---|
| Ａｎａｌｙｔｉｃａｌ Ｂｉｏｃｈｅｍｉｓｔｒｙ、２０１６年３月、Ｖ．５０１、Ｐ．６６－７４ |
| ＡＮＤＲＯＬＯＧＹ、２０１５年、Ｖｏｌ．３、Ｐ．７８－８４ |
| Ｅｎｄｏｃｒｉｎｅ－Ｒｅｌａｔｅｄ Ｃａｎｃｅｒ、２０１２年、Ｖｏｌ．１９、Ｐ３６５－３７９ |
Also Published As
| Publication number | Publication date |
|---|---|
| US11643690B2 (en) | 2023-05-09 |
| PL3535417T3 (pl) | 2023-10-02 |
| AU2017353410A1 (en) | 2019-04-11 |
| WO2018083186A1 (en) | 2018-05-11 |
| ES2952061T3 (es) | 2023-10-26 |
| AU2017353410B2 (en) | 2023-04-13 |
| CA3038010A1 (en) | 2018-05-11 |
| EP3535417B1 (en) | 2023-06-07 |
| EP3535417B9 (en) | 2023-10-04 |
| US20200056243A1 (en) | 2020-02-20 |
| EP3535417A1 (en) | 2019-09-11 |
| JP2019532653A (ja) | 2019-11-14 |
| ES2952061T9 (es) | 2023-11-02 |
| CN109890979B (zh) | 2023-06-16 |
| CN109890979A (zh) | 2019-06-14 |
| JP2022088555A (ja) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hong et al. | Systematic evaluation of multiple qPCR platforms, NanoString and miRNA-Seq for microRNA biomarker discovery in human biofluids | |
| CN107475258B (zh) | 一种RNA circEPSTI1及其在三阴乳腺癌上的应用 | |
| KR20180029936A (ko) | 신규한 간암 진단용 바이오 마커 및 이의 용도 | |
| KR20200002241A (ko) | 비만 진단을 위한 마이크로RNA-26b 또는 마이크로RNA-4449 바이오마커 및 이의 용도 | |
| US20060063170A1 (en) | Determination of RNA quality | |
| JP2022088555A (ja) | 前段階の精巣胚細胞腫瘍の早期発見 | |
| US20230304081A1 (en) | Primer and probe design method, detection composition, and kit for mirna detection | |
| JP6698696B2 (ja) | 核酸分子の検出 | |
| CN111041098B (zh) | 检测富脯氨酸和卷曲蛋白2a表达水平的试剂的应用和试剂盒 | |
| KR102110050B1 (ko) | 당뇨병 진단을 위한 마이크로rna-423 또는 마이크로rna-424 바이오마커 및 이의 용도 | |
| HK40013273A (en) | Early detection of preliminary stages of testicular germ cell tumors | |
| HK40013273B (en) | Early detection of preliminary stages of testicular germ cell tumors | |
| CN108611417A (zh) | 一种用于膀胱癌诊断的特异性表达图谱及分析系统 | |
| CA2641410A1 (en) | Genes for prognosis of cancer | |
| KR20200002237A (ko) | 비만 진단을 위한 마이크로RNA let-7a 또는 let-7f 바이오마커 및 이의 용도 | |
| WO2023074135A1 (ja) | 肺がんの予後の判定を補助する方法及び試薬キット | |
| KR101930818B1 (ko) | 방광암의 비침습적 진단 방법 | |
| KR20250078789A (ko) | 반려동물의 pik3ca 유전자 돌연변이성 종양 검출용 조성물 및 이를 이용한 반려동물의 pik3ca 유전자 돌연변이성 종양 진단방법 | |
| CN109825596A (zh) | 食管癌样本的内参miRNA及其应用 | |
| HK1251262B (en) | Detection of nucleic acid molecules | |
| HK1251262A1 (en) | Detection of nucleic acid molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201021 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201021 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210805 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210816 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211111 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220330 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220330 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220407 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220411 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220428 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220510 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220603 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230828 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231115 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7391367 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |